BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...financing experience from a stint at DRI Capital. Tao has held positions at J.P. Morgan, Deutsche Bank...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...last September when it hired Chief Strategy Officer and CFO Jack Hu, a 10-year veteran of Deutsche Bank...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...covered Asia and China healthcare as managing director and head of APAC healthcare research at Deutsche Bank...
BioCentury | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

...to joining Evercore in 2010, he worked for a decade as a biotech analyst at Deutsche Bank...
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...development. He was a managing director and head of U.S. life sciences investment banking at Deutsche Bank...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...bids include Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) and Zhejiang Jingxin Pharmaceutical Co Ltd. (SZSE:002020). Deutsche Bank's...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...bids include Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) and Zhejiang Jingxin Pharmaceutical Co Ltd. (SZSE:002020). Deutsche Bank's...
BioCentury | Aug 3, 2018
Financial News

BeiGene prices Hong Kong listing

...global investors. Underwriters include Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
BioCentury | Aug 2, 2018
Financial News

BeiGene prices Hong Kong listing

...US$861 million). Underwriters included Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
BioCentury | Jul 27, 2018
Financial News

BeiGene's proposed HKEX listing could rake in over $900M

...global investors. Underwriters include Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
Items per page:
1 - 10 of 867
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...financing experience from a stint at DRI Capital. Tao has held positions at J.P. Morgan, Deutsche Bank...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...last September when it hired Chief Strategy Officer and CFO Jack Hu, a 10-year veteran of Deutsche Bank...
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

...covered Asia and China healthcare as managing director and head of APAC healthcare research at Deutsche Bank...
BioCentury | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

...to joining Evercore in 2010, he worked for a decade as a biotech analyst at Deutsche Bank...
BioCentury | May 2, 2019
Company News

Management tracks: Akero, NIH, Arcus

...development. He was a managing director and head of U.S. life sciences investment banking at Deutsche Bank...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...bids include Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) and Zhejiang Jingxin Pharmaceutical Co Ltd. (SZSE:002020). Deutsche Bank's...
BioCentury | Dec 7, 2018
Company News

Chinese biopharma stocks plummet after centralized tendering report

...bids include Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) and Zhejiang Jingxin Pharmaceutical Co Ltd. (SZSE:002020). Deutsche Bank's...
BioCentury | Aug 3, 2018
Financial News

BeiGene prices Hong Kong listing

...global investors. Underwriters include Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
BioCentury | Aug 2, 2018
Financial News

BeiGene prices Hong Kong listing

...US$861 million). Underwriters included Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
BioCentury | Jul 27, 2018
Financial News

BeiGene's proposed HKEX listing could rake in over $900M

...global investors. Underwriters include Morgan Stanley, Goldman Sachs (Asia), Credit Suisse (Hong Kong), CLSA, CICC, Deutsche Bank...
Items per page:
1 - 10 of 867